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ABSTRACT
Background. This article summarizes the ERA-EDTA Registry’s 2016 Annual Report, by describing the epidemiology of renal
replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries.
Methods. In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52
national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data.
The incidence and prevalence of RRT and the survival probabilities of these patients were determined.
Results. In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to
251 pmp in Greece. Almost two-thirds of patients were men, over half were aged 65 years and almost a quarter had
diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of
patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in
Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of
Catalonia. For patients commencing RRT during 2007–11, the 5-year unadjusted patient survival probability on all RRT
modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and
1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with
women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007–11, the adjusted
patient survival probabilities appeared to be higher for women than for men.
Keywords: dialysis, end-stage renal disease, epidemiology, kidney transplantation, survival analysis
ERA-EDTA Registry Annual Report 2016 | 703
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/12/5/702/5364536 by N
ational Library of H
ealth Sciences user on 21 February 2020
INTRODUCTION
The European Renal Association – European Dialysis and
Transplant Association (ERA-EDTA) Registry’s Annual Report
describes the epidemiology of renal replacement therapy (RRT)
for end-stage renal disease (ESRD) within Europe and countries
bordering the Mediterranean Sea, based on the data collected via
national and regional renal registries [1]. The summary of the
ERA-EDTA Registry Annual Report, which is published on an an-
nual basis, is intended to provide an overview of the current sta-
tus of RRT for ESRD in Europe [2–4]. In 2017 and 2018, data for the
year 2016 were received from 52 national or regional renal regis-
tries in 36 countries covering a general population of 686.9 mil-
lion people. When leaving out Israel and Tunisia, the remaining
countries cover a general population of 677.3 million people, rep-
resenting 80.5% of the 2016 European general population, which
was similar to 2015 (80.3%). A total of 32 national or regional re-
nal registries from 17 countries provided individual patient data,
whereas 20 countries or regions provided aggregated data (see
Appendix A1). Compared to the 2015 ERA-EDTA Registry Annual
Report, there were no differences in country participation.
This summary presents the 2016 incidence and prevalence
of RRT, kidney transplantation activity, and the patient and
graft survival. A description of the methods used to analyse the
data, along with the full results, can be found in the ERA-EDTA
Registry 2016 Annual Report [1].
On the occasion of the 2018 global focus on kidneys and
women’s health, this year’s annual report contains additional
analyses on sex comparisons, a summary of which is also pre-
sented in this article.
RESULTS
Incidence of RRT
In 2016, 83 311 individuals commenced RRT for ESRD, which
equated to an overall unadjusted incidence of 121 per million pop-
ulation (pmp; Table 1). The unadjusted incidence was highest in
Greece (251 pmp), Czech Republic (243 pmp) and Portugal
(236 pmp), whereas it was lowest in Ukraine (29 pmp) and Russia
(59 pmp; Table 1 and Figures 1 and 2). Of the patients commencing
RRT, 62% were men, 52% were aged 65 years and 23% had diabe-
tes mellitus (DM) as their primary renal diagnosis (Figure 3). The
median age of the patients commencing RRT in all countries and
regions combined was 65.8 years, ranging from 51.0 years in
Ukraine to 73.8 years in the Dutch-speaking part of Belgium
(Table 1). The majority of patients started RRT with haemodialysis
(HD; 84%), while 12% of patients started with peritoneal dialysis
(PD) and 4% received a pre-emptive kidney transplant (Figure 4).
However, the initial treatment modality varied considerably be-
tween age groups, as the proportion of patients receiving either
PD or a pre-emptive transplant decreased with increasing age.
Furthermore, patients with a primary renal diagnosis of DM were
less likely to receive a pre-emptive kidney transplant compared
with non-diabetic patients (2% versus 6%). Of the incident patients
receiving RRT at Day 91 after the start of treatment, the majority
(82%) were receiving HD, 13% were receiving PD and 5% were liv-
ing with a kidney transplant (Figure 5). In the first 90 days of treat-
ment, the percentage of patients receiving HD decreased, and this
was particularly evident in the younger age groups.
Prevalence of RRT
On 31 December 2016, 564 638 individuals were receiving RRT
for ESRD (Table 2), corresponding to an overall unadjusted
prevalence of 823 pmp. Again, there was considerable variation
between countries, with the highest unadjusted prevalence
seen in Portugal (1906 pmp) and the Spanish regions of
Catalonia (1399 pmp) and Valencia (1388 pmp; Table 2 and
Figures 6 and 7). The unadjusted prevalence of RRT was consid-
erably lower in Ukraine (188 pmp) and Belarus (289 pmp). The
top five countries with the highest prevalence of RRT have
remained the same since 2014. Of the prevalent patients, 60%
were men, 42% were aged 65 years and 17% had DM as their
primary renal diagnosis (Figure 8). The median age of prevalent
patients receiving RRT in all countries and regions combined
was 62.4 years, ranging from 50.7 years in Albania to 68.0 years
in Israel (Table 2). The majority of prevalent patients (58%) were
receiving HD, 37% of patients were living with a kidney trans-
plant and only 5% were receiving PD (Figure 9). Once again the
modality of RRT varied considerably between age groups as the
proportion of patients with a kidney transplant decreased with
increasing age. For those aged 20–44 years, 66% were living with
a kidney transplant, whereas this was only 42% for patients
aged 65–74 years. Prevalent patients with a primary renal diag-
nosis of DM were much less likely to be living with a kidney
transplant compared with the patients without DM (28% versus
50%).
Kidney transplantation
In 2016, 22 046 kidney transplantations were performed, which
equated to an overall unadjusted transplant rate of 32 pmp
(Figure 10). Again there was considerable variation between
countries/regions with unadjusted kidney transplant rates
well over 70 pmp in several Spanish regions, and very low
unadjusted kidney transplant rates in Ukraine (3 pmp) and
Macedonia (3 pmp). Overall, the unadjusted deceased donor
kidney transplant rate was more than twice that of the unad-
justed living donor transplant rate (22 pmp versus 9 pmp; 70%
versus 30%; Figure 11). The highest unadjusted rates of de-
ceased donor kidney transplants were seen in some Spanish
regions (>70 pmp; Figure 12), whereas the highest unadjusted
rate of living donor transplants was seen in Northern Ireland
(38 pmp), the Netherlands (33 pmp) and Turkey (33 pmp;
Figure 12).
Survival of patients receiving RRT
For patients commencing RRT in the period 2007–11, the 5-year
unadjusted patient survival probability for all RRT modalities
combined was 50.5% [95% confidence interval (CI) 50.4–50.6]. For
patients commencing RRT with dialysis between 2007 and 2011,
the 5-year unadjusted patient survival probability was 42.1%
(95% CI 42.0–42.3). Adjusted analyses for patient survival on HD
and PD revealed higher survival probabilities in the first 3 years
for patients receiving PD (Figure 13). For those with a kidney
transplant, 5-year adjusted patient and graft survival were
higher for living donor transplants compared with deceased do-
nor transplants: 94.6% (95% CI 94.1–95.1) versus 91.9% (95% CI
91.6–92.3) for patient survival and 86.7% (95% CI 85.9–87.4) ver-
sus 80.9% (95% CI 80.4–81.4) for graft survival. See Table 3 for a
description of the adjustments made and the countries/regions
included in these analyses.
Expected remaining lifetime
There is still a substantial difference in the expected remaining
lifetime between the general population and those receiving di-
alysis (Figure 14). Patients aged 20–44 years receiving dialysis
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Table 1. Incidence of RRT in 2016 at Day 1, by country/region, for all primary renal diseases combined and DM types 1 and 2, as count (n) and
unadjusted rate pmp, and the mean and median age at the start of RRT
Country/region
General population covered by
the registry in thousands
Incidence of RRT in 2016, at Day 1
All (n) All (pmp) Mean age (years) Median age (years) DM (n) DM (pmp)
Albania 2860 252 88 52.6 52.2 50 17
Austria 8700 1155 133 64.4 67.3 305 35
Belarus 8172 504 62 53.0 54.0 92 11
Belgium, Dutch-speakinga 6509 1214 187 71.0 73.8 256 39
Belgium, French-speakinga 4822 906 188 67.3 69.3 202 42
Bosnia and Herzegovina 3531 397 112 62.2 63.9 131 37
Bulgaria 7102 1109 156 309 44
Croatia 3755 675 180 64.9 66.0 181 48
Cyprus 857 165 193 66.7 69.0 47 55
Czech Republicb 10 262 2496 243
Denmark 5784 740 128 63.3 67.4 192 33
Estonia 1316 112 85 59.7 61.6 19 14
Finland 5495 560 102 60.9 63.8 189 34
France 66 860 11 033 165 67.9 70.6 2566 38
Georgia 3720 754 203 60.4 61.9 187 50
Greece 10 776 2702 251 70.8 73.6 710 66
Iceland 335 30 89 61.7 65.1 5 15
Israel 8545 1612 189 65.1 68.0 805 94
Italy (6 of 20 regions) 20 921 3023 144 68.8 71.8 522 25
Latvia 1560 171 110 60.3 63.0 26 17
Lithuania 2888 310 107 61.8 62.5 52 18
Macedonia 2022 332 164 63.7 65.0 84 42
Norway 5235 556 106 63.1 66.5 88 17
Polandb 38 362 5716 149 2098 55
Portugal 10 358 2446 236 757 73
Romania 19 505 3454 177 62.4 64.5 356 18
Russiab 143 869 8521 59 54.3 57.0 1491 10
Serbiac 7058 618 88 62.0 64.6 139 20
Slovakiab 5435 835 154 64.6 66.0 316 58
Spain (All regions) 46 558 6600 142 63.0 67.5 1610 35
Spain, Andalusia 8406 1133 135 63.5 66.0 294 35
Spain, Aragon 1317 165 125 63.5 67.3 39 30
Spain, Asturias 1041 188 181 64.8 66.6 41 39
Spain, Basque country 2166 284 131 63.4 65.4 57 26
Spain, Cantabriaa 582 59 101 63.1 67.7 12 21
Spain, Castile and Leo´na 2445 308 126 68.1 71.3 85 35
Spain, Castile-La Manchaa 2045 287 140 66.1 69.1 67 33
Spain, Catalonia 7523 1260 167 65.9 68.7 261 35
Spain, Extremadura 1088 120 110 65.6 66.6 34 31
Spain, Galicia 2715 399 147 66.0 68.7 102 38
Spain, Community of Madrid 6467 870 135 64.9 67.7 227 35
Spain, Region of Murcia 1465 202 138 63.3 65.3 47 32
Spain, Navarrea 639 82 128 64.7 67.2 21 33
Spain, Valencian region 4960 858 173 65.8 68.9 178 36
Sweden 9923 1204 121 64.0 67.9 324 33
Switzerland 8373 844 101 63.8 66.6 181 22
The Netherlands 16 349 1906 117 64.2 67.4 368 23
Tunisia, Sfax regionb 1213 193 159 60.5 63.0 62 51
Turkeyd 79 815 11 169 140 787 10
UK, Englanda,e 55 268 6454 117 62.3 64.4 1618 29
UK, Northern Irelanda 1862 225 121 62.8 66.4 55 30
UK, Scotland 5405 571 106 59.2 61.6 171 32
UK, Walesa 3113 370 119 64.9 66.5 92 30
Ukraine 42 590 1246 29 49.7 51.0 303 7
All countries 687 084 83 311 121 63.1 65.8 17 757 29
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients <20 years of age are not reported. The true incidence counts are, therefore, slightly higher than the counts reported here.
bData on incidence include dialysis patients only.
cThe incidence is underestimated by 29% due to centres not submitting complete data for 2016.
dData on incidence of primary renal disease (DM) is based on 2078 dialysis patients (18.6% of total).
eThe incidence is underestimated by 2% due to a small number of centres not submitting complete data for 2016.
DM, diabetes mellitus as primary renal disease.
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FIGURE 1: Incidence of RRT pmp in 2016, at Day 1, by country/region, unadjusted. The incidence for Czech Republic, Poland, Russia, Slovakia and Tunisia (Sfax region)
only includes patients receiving dialysis. For Serbia and England (UK), the incidence is underestimated by, respectively, 26% and 2% (see Table 1).
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FIGURE 2: Unadjusted (left panel) and adjusted (right panel) incidence of RRT pmp in 2016, at Day 1, by country/region. Registries providing individual patient data are
shown as dark bars, and registries providing aggregated data as light bars. Adjustment of incidence was performed by standardizing the rates to the age and gender
distribution of the EU27 population [5]. The incidence for Czech Republic, Poland, Russia, Slovakia and Tunisia (Sfax region) only includes patients receiving dialysis.
For Serbia and England (UK), the incidence is underestimated by, respectively, 26% and 2% (see Table 1).
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are expected to live only one-third of the expected remaining
lifetime of the age-matched general population, which is about
33 years less. The prospect is even worse for patients aged 45–
64 years, as they are expected to live only a quarter as long as
their age-matched counterparts in the general population
(21 years less). Patients living with a kidney transplant fare
better than those receiving dialysis. However, the life expec-
tancy of the transplant recipients aged 20–44 years is still 30%
less than that of the age-matched general population (15 years
less). Thus, as the age of the transplant recipient increases, the
relative difference in the expected remaining lifetime from that
of the age-matched general population also increases although
the absolute difference decreases.
Sex comparisons
Figures 15–31 showing comparisons of the sexes are based on
the data from 32 national or regional renal registries from 17
countries that provided individual patient data, representing
33.8% of the 2016 European general population.
In 2016, 26 446 men and 14 820 women commenced RRT
resulting in a higher unadjusted incidence among men
(187 pmp) than women (101 pmp). This was the case for all age
groups, with the incidence in men aged 75 years (807 pmp) be-
ing 2.7 times that of women aged 75 years (300 pmp;
Figure 15). In men and women commencing RRT, the distribu-
tion of the age groups was very similar (Figure 16). About 36% of
patients commencing RRT were female, decreasing from around
FIGURE 3: (A) Sex, (B) age and (C) primary renal disease distribution by type of
data provided for incident patients accepted for RRT in 2016, at Day 1. See
Appendix A1 for a list of countries and regions supplying individual patient data
or aggregated data.
FIGURE 4: Treatment modality distribution, at Day 1, by (A) type of data provided
(B) age and (C) primary renal diagnosis (DM and non-DM) for incident patients
accepted for RRT in 2016. Parts (B) and (C) are only based on the data from regis-
tries providing individual patient data. See Appendix A1 for a list of countries
and regions supplying individual patient data or aggregated data. Tx, kidney
transplant.
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39% of patients <45 years at the start of RRT to about 36% of
patients aged 45 years (Figure 17).
Diabetes was the most frequent primary renal disease in
both men and women starting RRT (Figure 18). The incidence of
men starting RRT for ESRD due to glomerulonephritis/sclerosis
(23 pmp) and hypertension (29 pmp) was more than double that
of their female counterparts (10 and 13 pmp, respectively), while
the incidence of polycystic kidney disease in men (9 pmp) was
only about 30% higher than in women (7 pmp). When viewed by
sex, the distribution of the primary renal disease was similar. Of
the men commencing RRT, 16% had hypertension and 12% had
glomerulonephritis/sclerosis, and for women this was 13 and
10%, respectively (Figure 19).
The incidence of all treatment modalities was higher among
men than women (Figure 20). Of the men and women initiating
RRT in 2016, the majority started with HD (82 and 81%, respec-
tively; Figure 21). Although more men (8 pmp) than women
(5 pmp) received a pre-emptive transplant, the percentage of
patients starting RRT with a pre-emptive transplant was similar
among men (4%) and women (5%).
On 31 December 2016, 195 810 men and 121 755 women were
receiving RRT for ESRD, resulting in a higher prevalence of RRT
among men (1381 pmp) than women (827 pmp), which was the
case for all age groups (Figure 22). In men, the highest preva-
lence was found in the group aged 75 years, whereas in
women the highest prevalence was found in the group aged 65–
74 years. The age distribution of patients receiving RRT was sim-
ilar for both sexes, with most patients in the 45- to 64-year age
group (39%; Figure 23). The percentage of women within the dif-
ferent age groups varied between 37% among patients aged 65–
74 years and 40% among patients aged 0–19 years (Figure 24).
The prevalence of men on RRT with glomerulonephritis/sclero-
sis and hypertension (301 and 167 pmp) was more than twice
that of women (140 and 75 pmp; Figure 25). For men receiving
RRT, the most frequent primary renal disease was glomerulone-
phritis/sclerosis (22%), while for women their most frequent pri-
mary renal disease category was ‘miscellaneous’ (Figure 26,
Appendix 2). For both men and women, the majority of patients
were receiving HD (668 and 399 pmp), and slightly fewer men
and women were living with a kidney transplant (642 and
382 pmp, respectively; Figure 27). The distribution of treatment
modalities was similar across the sexes (Figure 28).
In 2016, 8355 kidney transplantations were performed in
men, and 4827 in women, equating to transplant rates of 59 and
33 pmp, respectively (Figure 29). For men, 22% of the transplants
came from living donors, and for women 24% (Figure 30).
For patients commencing RRT with dialysis in the period
2007–11, for both HD and PD, the adjusted patient survival prob-
abilities were higher for women than for men (Figure 31). For
both men and women receiving a kidney transplant in the pe-
riod 2007–11, the adjusted patient survival was higher with a liv-
ing donor transplant compared with a deceased donor
transplant, and this difference was more prominent in men
than in women.
AFFILIATED REGISTRIES
Albanian Renal Registry (M. Barbullushi, A. Idrizi and E. Bolleku
Likaj); Austrian Dialysis and Transplant Registry [OEDTR] (R.
Kramar); Belarus Renal Registry (K.S. Komissarov, K.S.
Kamisarau and A.V. Kalachyk); Dutch-speaking Belgian Society
of Nephrology [NBVN] (M. Couttenye, F. Schroven and J. De
Meester); French-speaking Belgian Society of Nephrology [GNFB]
(JM. des Grottes and F. Collart); Renal Registry Bosnia and
Herzegovina (H. Resic, Z. Stipancic and N. Petkovic); Bulgaria
(E.S. Vazelov and I. Velinova); Croatian Registry of renal replace-
ment therapy [CRRRT] (I. Bubic and M. Knotek); Cyprus Renal
Registry (K. Ioannou and all of the renal units providing data);
Czech Republic: Registry of Dialysis Patients [RDP] (I. Rychlı´k, J.
Potucek, and F. Lopot); Danish Nephrology Registry [DNS] (J.G.
Heaf); Estonian Society of Nephrology (U¨. Pechter, K. Lilienthal
and M. Rosenberg); Finnish Registry for Kidney Diseases (P.
Finne, A. Pylsy and P.H. Groop); France: The Epidemiology and
Information Network in Nephrology [REIN] (M. Lassalle and C.
Couchoud); Georgian Renal Registry (N. Kantaria and Dialysis
Nephrology and Transplantation Union of Georgia); Hellenic
Renal Registry (N. Afentakis); Icelandic ESRD Registry (R.
FIGURE 5: Treatment modality distribution, at Day 91, by (A) type of data pro-
vided, (B) age and (C) primary renal diagnosis (DM and non-DM) for incident
patients accepted for RRT in 2016. Parts (B) and (C) are only based on the data
from registries providing individual patient data. See Appendix A1 for a list of
countries and regions supplying individual patient data or aggregated data. Tx,
kidney transplant.
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Table 2. Prevalence of RRT on 31 December 2016, by country/region, for all primary renal diseases combined and DM types 1 and 2, as count
(n) and unadjusted rate pmp, and the mean and median age on 31 December 2016
Country/region
General population covered by
the registry in thousands
Prevalent patients on RRT in 2016
All (n) All (pmp) Mean age (years) Median age (years) DM (n) DM (pmp)
Albania 2860 1450 507 49.6 50.7 230 80
Austria 8700 9397 1080 61.2 62.7 1848 212
Belarus 8172 2360 289 51.6 53.0 295 36
Belgium, Dutch-speakinga 6509 8257 1269 66.1 67.9 1426 219
Belgium, French-speakinga 4822 6317 1310 64.9 66.5 1109 230
Bosnia and Herzegovina 3531 2679 759 59.7 61.7 548 155
Bulgaria 7102 4333 610
Croatia 3755 3908 1041 65.7 67.0 710 189
Cyprus 857
Czech Republic 10 262 11 265 1098
Denmark 5784 5433 939 58.8 60.4 929 161
Estonia 1316 919 698 57.9 58.6 168 128
Finland 5495 4861 885 59.2 61.5 1231 224
France 66 860 85 471 1278 62.8 64.6 13 833 207
Georgia 3720 2652 713 60.1 61.2 539 145
Greece 10 776 13 841 1284 64.6 66.8 2637 245
Iceland 335 224 668 54.9 56.3 26 78
Israelb 8545 6566 768 66.0 68.0 3035 355
Italy (6 of 20 regions) 20 921 24 035 1149 62.0 64.1 2654 127
Latvia 1560 1038 665 56.3 57.0 98 63
Lithuania 2888 2193 759
Macedonia 2022 1665 823 58.6 60.0 273 135
Norway 5235 4974 950 59.4 61.5 654 125
Poland 38 362 31 144 812 6132 160
Portugal 10 358 19 738 1906 66.9 67.9 3435 332
Romaniac 19 505 20 445 1048 61.2 63.0 2051 105
Russia 1 43 869 44 544 310 55.5 57.0 5340 37
Serbiad 7058 3833 543 59.5 62.0 640 91
Slovakiab 5435 3370 620 63.8 66.0 1140 210
Spain (All regions) 46 558 57 433 1234 60.0 63.2 9031 194
Spain, Andalusia 8406 10 019 1192 60.5 61.9 1548 184
Spain, Aragon 1317 1588 1205 62.9 64.0 274 208
Spain, Asturias 1041 1325 1273 63.0 63.5 215 207
Spain, Basque country 2166 2704 1249 62.0 63.8 304 140
Spain, Cantabriaa 582 686 1179 62.6 64.0 91 156
Spain, Castile and Leo´na 2445 2858 1169 64.8 65.8 505 207
Spain, Castile-La Manchaa 2045 2357 1153 62.5 63.3 373 182
Spain, Catalonia 7523 10 523 1399 63.0 64.8 1499 199
Spain, Community of Madrid 6467 7450 1152 61.9 63.2 1323 205
Spain, Extremadura 1088 1263 1161 62.0 62.3 191 176
Spain, Galicia 2715 3619 1333 62.5 64.0 598 220
Spain, Navarrea 639 837 1310 62.5 64.0 128 200
Spain, Region of Murcia 1465 1949 1331 62.1 63.3 274 187
Spain, Valencian region 4960 6883 1388 63.3 65.2 933 188
Sweden 9923 9718 979 59.9 62.0 1742 176
Switzerlande 8373 7503 896 62.1 63.9 1159 138
The Netherlands 16 349 17 117 1047 60.5 62.4 2229 136
Tunisia, Sfax regionb 1213 946 780 58.2 59.0 200 165
Turkeyf 79 815 74 475 933 2719 34
UK, Englanda,g 55 268 52 641 952 58.8 59.2 8884 161
UK, Northern Irelanda 1862 1784 958 58.7 58.4 280 150
UK, Scotland 5405 5028 930 56.8 57.7 826 153
UK, Walesa 3113 3062 984 59.5 60.3 503 162
Ukraine 42 590 8019 188 49.5 51.0 1280 30
All countries 687 084 564 638 823 60.6 62.4 79 834 134
When cells are left empty, the data are unavailable and could not be used for the calculation of the summary data.
aPatients <20 years of age are not reported. The true prevalent counts are therefore slightly higher than the counts reported here.
bData on prevalence include dialysis patients only.
cThe prevalence is underestimated by 3% due to an estimated 30% under-reporting of patients living with a functioning graft.
dThe prevalence is underestimated by 29% due to centres not submitting complete data for 2016.
eThe prevalence is underestimated by 6% due to an estimated 11% under-reporting of patients living with a functioning graft.
fData on the prevalence of primary renal disease (DM) is based on 8043 dialysis patients (10.8% of total)
gThe prevalence is underestimated by 1% due to a small number of centres not submitting complete data for 2016.
DM, diabetes mellitus as primary renal disease.
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FIGURE 6: Prevalence of RRT pmp on 31 December 2016 by country/region. The prevalence for Israel only includes patients receiving dialysis. For Romania, Serbia,
Switzerland and England (UK), the prevalence is underestimated by, respectively, 30, 29, 6 and 1% (see Table 2).
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FIGURE 7: Unadjusted (left panel) and adjusted (right panel) prevalence of RRT pmp on 31 December 2016 by country/region. Registries providing individual patient
data are shown as dark bars, and registries providing aggregated data as light bars. Adjustment of the prevalence was performed by standardizing the prevalence to
the age and gender distribution of the EU27 population [5]. The prevalence for Israel only includes patients receiving dialysis. For Romania, Serbia, Switzerland and
England (UK), the prevalence is underestimated by, respectively, 30, 29, 6 and 1% (see Table 2).
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Palsson); Israel National Registry of Renal Replacement Therapy
(R. Dichtiar, T. Shohat and E. Golan); Italian Registry of Dialysis
and Transplantation [RIDT] (A. Limido, M. Nordio and M.
Postorino); Latvian Renal Registry (H. Cernevskis, V. Kuzema
and A. Silda); Lithuanian Renal Registry (I.A. Bumblyte, V.
Vainauskas and E. Ziginskien _e); Macedonian Renal Registry (M.
Nedelkovska, N. Dimitriova and O. Stojceva-Taneva);
Norwegian Renal Registry (T. Leivestad, A.V. Reisæter and A.
A˚sberg); Polish Renal Registry (G. Korejwo, A. De˛bska-Slizien and
R. Gellert); Portuguese Renal Registry (F. Maca´rio and A.
Ferreira); Romanian Renal Registry [RRR] (G. Mircescu, L.
Garneata and E. Podgoreanu); Russian Renal Registry (N.
Tomilina, A. Andrusev and H. Zakharova); Renal Registry in
Serbia (N. Maksimovic, R. Naumovic, all of the Serbian renal
units, and the Serbian Society of Nephrology); Slovakian Renal
Registry (V. Spustova´, I. Lajdova´ and M. Karolyova); Spanish RRT
National Registry at ONT, Spanish Regional Registries and
Spanish Society of Nephrology (SEN) and the regional registries
of Andalusia [SICATA] [P. Castro de la Nuez (on behalf of all
users of SICATA)], Aragon (F. Arribas Monzo´n, J.M. Abad Diez
and J.I. Sanchez Miret), Asturias (R. Alonso de la Torre, J.R.
Quiro´s and RERCA Working Group), Basque country [UNIPAR]
(A´. Magaz, J. Aranzabal, M. Rodrigo and I. Moina), Cantabria (J.C.
Ruiz San Milla´n, O. Garcia Ruiz and C. Pi~nera Haces), Castile and
Leo´n (M.A. Palencia Garcı´a), Castile-La Mancha (G. Gutie´rrez
A´vila and I. Moreno Alı´a), Catalonia [RMRC] (E. Arcos, J. Comas
and J. Tort), Extremadura (J.M. Ramos Aceitero and M.A. Garcı´a
Bazaga), Galicia (E. Bouzas-Caama~no), Community of Madrid
(M.I. Aparicio de Madre), Renal Registry of the Region of Murcia
(C. Santiuste de Pablos and I. Marı´n Sa´nchez), Navarre (M.F. Slon
FIGURE 8: (A) Sex, (B) age and (C) primary renal disease distribution by type of
data provided for prevalent patients on RRT on 31 December 2016. See Appendix
A1 for a list of countries and regions supplying individual patient data or aggre-
gated data.
FIGURE 9: Treatment modality distribution by (A) type of data provided (B) age
and (C) primary renal diagnosis (DM and non-DM) for prevalent patients on RRT
on 31 December 2016. Parts (B) and (C) are only based on the data from registries
providing individual patient data. See Appendix A1 for a list of countries and
regions supplying individual patient data or aggregated data. Tx, kidney
transplant.
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FIGURE 10: Kidney transplants performed in 2016, as counts and pmp (unadjusted) by country/region. Registries providing individual patient data are shown as dark
bars, and registries providing aggregated data as light bars. Data based on patients aged 20 years in Dutch-speaking Belgium, French-speaking Belgium, the Spanish
regions of Cantabria, Castile and Leo´n, Castile-La Mancha and Navarre and UK: England, Northern Ireland and Wales. The total count for Austria is based on residents
and non-residents. For Romania, Serbia, Switzerland and England (UK), the overall kidney transplant rate is underestimated by, respectively, 30, 36, 6 and 7%.
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Roblero, J. Manrique Escola and J. Arteaga Coloma) and the
Valencian region [REMRENAL] (M. Ferrer Alamar, N. Fuster
Camarena and J. Pe´rez Penade´s); Swedish Renal Registry [SNR]
(K.G. Pru¨tz, M. Stendahl, M. Evans, S. Scho¨n, T. Lundgren and M.
Segelmark); Swiss Dialysis Registry (P. Ambu¨hl and R. Winzeler);
Dutch Renal Registry [RENINE] (L. Heuveling, S. Vogelaar and M.
Hemmelder); Tunisia, Sfax region (F. Jarraya and D. Zalila);
Registry of the Nephrology, Dialysis and Transplantation in
Turkey [TSNNR] (G. Su¨leymanlar, N. Seyahi and K. Ates¸);
Ukrainian Renal Data System [URDS] (M. Kolesnyk, S.
Nikolaenko and O. Razvazhaieva); United Kingdom Renal
Registry [UKRR] (all the staff of the UK Renal Registry and of the
renal units submitting data); Scottish Renal Registry [SRR] (all of
the Scottish renal units).
FIGURE 11: Donor-type distribution for kidney transplants performed in 2016, by
type of data provided. See Appendix A1 for a list of countries and regions sup-
plying individual patient data or aggregated data.
FIGURE 12: Deceased donor (left panel) and living donor (right panel) kidney transplants performed in 2016 pmp, by country/region, unadjusted. Registries providing in-
dividual patient data are shown as dark bars, and registries providing aggregated data as light bars. Data based on patients aged 20 years in Dutch-speaking Belgium,
French-speaking Belgium, the Spanish regions of Cantabria, Castile and Leo´n, Castile-La Mancha and Navarre and UK: England, Northern Ireland and Wales. The total
count for Austria is based on residents and non-residents. For Romania, Switzerland and England (UK), the kidney transplant rate is underestimated by, respectively,
30, 6 and 7%. For Serbia, the transplant rate is underestimated by 29% for deceased donor transplants and by 39% for living donor transplants.
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FIGURE 13: Patient survival of patients starting HD and PD between 2007 and 2011 from Day 91 (left panel) and patients receiving a first kidney transplant from a living
or deceased donor between 2007 and 2011 (right panel). Survival on dialysis was censored for transplantation, and adjusted using fixed values for age (67 years), gender
(63% men) and primary renal disease (24% DM, 19% hypertension/renal vascular disease, 11% glomerulonephritis and 46% other causes). Survival after kidney trans-
plantation was adjusted using fixed values for age (50 years), gender (63% men) and primary renal disease (14% DM, 10% hypertension/renal vascular disease, 23% glo-
merulonephritis and 53% other causes). These figures are based on the data from the following registries providing individual patient data: Austria, Belgium (Dutch-
speaking), Belgium (French-speaking), Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country),
Spain (Cantabria), Spain (Castile and Leo´n), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain
(Valencian region), Sweden, the Netherlands and the UK (all countries).
Table 3. The survival probabilities at 1, 2 and 5years by treatment modality and cohort, from Day 1 of the start of RRT/dialysis, or from the day
of kidney transplantation
Survival probabilities as percentage (95% CI)
Cohort: 2007–11 Cohort: 2010–14
Survival type 1 year 2 years 5 years 1 year 2 years
Patient survival on RRT
Unadjusted 83.6 (83.4–83.7) 73.2 (73.1–73.4) 50.5 (50.4–50.6) 84.6 (84.4–84.7) 74.6 (74.5–74.8)
Adjusteda 86.3 (86.1–86.4) 76.6 (76.4–76.9) 51.7 (51.5–52.0) 87.1 (86.9–87.3) 77.9 (77.7–78.1)
Patient survival on dialysis
Unadjusted 82.5 (82.4–82.7) 70.8 (70.6–71.0) 42.1 (42.0–42.3) 83.5 (83.3–83.6) 72.1 (71.9–72.2)
Adjusteda 84.7 (84.5–84.9) 74.0 (73.7–74.2) 45.5 (45.2–45.8) 85.9 (85.7–86.0) 75.6 (75.4–75.8)
Patient survival after first kidney transplantation (deceased donor)
Unadjusted 96.3 (96.1–96.5) 94.4 (94.1–94.6) 87.7 (87.3–88.0) 96.3 (96.1–96.5) 94.3 (94.0–94.5)
Adjustedb 97.7 (97.5–97.9) 96.4 (96.2–96.6) 91.9 (91.6–92.3) 97.9 (97.8–98.1) 96.7 (96.5–96.9)
Graft survival after first kidney transplantation (deceased donor)
Unadjusted 91.1 (90.7–91.4) 88.2 (87.9–88.5) 78.7 (78.3–79.1) 91.0 (90.8–91.3) 88.0 (87.7–88.3)
Adjustedb 92.1 (91.8–92.4) 89.6 (89.2–89.9) 80.9 (80.4–81.4) 92.6 (92.3–92.9) 90.0 (89.7–90.4)
Patient survival after first kidney transplantation (living donor)
Unadjusted 98.7 (98.4–98.9) 97.8 (97.4–98.0) 94.1 (93.6–94.5) 99.1 (98.9–99.2) 98.1 (97.9–98.4)
Adjustedb 98.8 (98.6–99.1) 98.0 (97.7–98.3) 94.6 (94.1–95.1) 99.2 (99.1–99.4) 98.5 (98.2–98.7)
Graft survival after first kidney transplantation (living donor)
Unadjusted 95.9 (95.5–96.3) 94.1 (93.6–94.5) 87.5 (86.9–88.0) 96.8 (96.5–97.1) 95.1 (94.7–95.4)
Adjustedb 95.6 (95.2–96.1) 93.7 (93.2–94.2) 86.7 (85.9–87.4) 96.6 (96.3–97.0) 94.8 (94.4–95.2)
This is based on the data from the following renal registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking),
Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and
Leo´n), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Valencian region), Sweden, the
Netherlands and the UK (all countries).
aAnalyses were adjusted using fixed values: age (67 years), gender (63% men) and primary renal disease (24% DM, 19% hypertension/renal vascular disease, 11% glomer-
ulonephritis and 46% other causes).
bAnalyses were adjusted using fixed values: age (50 years), gender (63% men) and primary renal disease (14% DM, 10% hypertension/renal vascular disease, 23% glomer-
ulonephritis and 53% other causes).
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FIGURE 14: Expected remaining lifetimes of the general population (cohort 2012–16), and of prevalent dialysis and kidney transplant patients (cohort 2012–16), by age
and gender. This figure is based on data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking),
Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque Country), Spain (Cantabria), Spain (Castile and
Leo´n), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Valencian region), Sweden, the
Netherlands and the UK (all countries).
FIGURE 15: Incidence of RRT per million age-related population (pmarp) in 2016,
at Day 1, by age and sex. Figure is only based on the data from registries provid-
ing individual patient data (see Appendix A1).
FIGURE 16: Age distribution by sex for incident patients accepted for RRT in
2016, at Day 1. Figure is only based on the data from registries providing individ-
ual patient data (see Appendix A1).
FIGURE 17: Sex distribution by age for incident patients accepted for RRT in
2016, at Day 1. Figure is only based on the data from registries providing individ-
ual patient data (see Appendix A1).
FIGURE 18: Incidence of RRT pmp in 2016, at Day 1, by primary renal disease and
sex. Figure is only based on the data from registries providing individual patient
data (see Appendix A1).
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FIGURE 19: Primary renal disease distribution by sex for incident patients ac-
cepted for RRT in 2016, at Day 1. Figure is only based on the data from registries
providing individual patient data (see Appendix A1).
FIGURE 20: Incidence of RRT pmp in 2016, at Day 1, by treatment modality and
sex. Figure is only based on the data from registries providing individual patient
data (see Appendix A1).
FIGURE 21: Treatment modality distribution by sex for incident patients ac-
cepted for RRT in 2016, at Day 1. Figure is only based on the data from registries
providing individual patient data (see Appendix A1). Tx, kidney transplant.
FIGURE 22: Prevalence of RRT pmarp on 31 December 2016, by age and sex.
Figure is only based on the data from registries providing individual patient data
(see Appendix A1).
FIGURE 23: Age distribution by sex for prevalent patients on RRT on 31
December 2016. Figure is only based on the data from registries providing indi-
vidual patient data (see Appendix A1).
FIGURE 24: Sex distribution by age for prevalent patients on RRT on 31
December 2016. Figure is only based on data from registries providing individual
patient data (see Appendix A1).
FIGURE 25: Prevalence of RRT pmp on 31 December 2016, by primary renal dis-
ease and sex. Figure is only based on data from registries providing individual
patient data (see Appendix A1).
FIGURE 26: Primary renal disease distribution by sex for prevalent patients on
RRT on 31 December 2016. Figure is only based on the data from registries pro-
viding individual patient data (see Appendix A1).
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FIGURE 27: Prevalence of RRT pmp on 31 December 2016, by treatment modality
and sex. Figure is only based on the data from registries providing individual pa-
tient data (see Appendix A1).
FIGURE 28: Treatment modality distribution by sex for prevalent patients on
RRT on 31 December 2016. Figure is only based on the data from registries pro-
viding individual patient data (see Appendix A1). Tx, kidney transplant.
FIGURE 29: Kidney transplants performed pmp in 2016, by donor type and sex.
Figure is only based on the data from registries providing individual patient data
(see Appendix A1).
FIGURE 30: Donor-type distribution for kidney transplants performed in 2016, by
sex. Figure is only based on the data from registries providing individual patient
data (see Appendix A1).
FIGURE 31: Patient survival of men and women starting HD and PD between 2007 and 2011 from Day 91 (left panel) and men and women receiving a first kidney trans-
plant from a living or deceased donor between 2007 and 2011 (right panel). Survival on dialysis was adjusted using fixed values for age (67 years) and primary renal dis-
ease (24% diabetes mellitus, 19% hypertension/renal vascular disease, 11% glomerulonephritis and 46% other causes). Survival after kidney transplantation was
adjusted using fixed values for age (50 years) and primary renal disease (14% diabetes mellitus, 10% hypertension/renal vascular disease, 23% glomerulonephritis and
53% other causes). These figures are based on the data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium
(French-speaking), Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria),
Spain (Castile and Leo´n), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Valencian region),
Sweden, the Netherlands and the UK (all countries).
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APPENDIX A1
Countries or regions providing individual patient data are:
Austria, Dutch-speaking Belgium, French-speaking Belgium,
Bosnia and Herzegovina, Denmark, Estonia, Finland, France,
Greece, Iceland, Norway, Romania, Serbia, the Spanish regions
of Andalusia, Aragon, Asturias, Basque country, Cantabria,
Castile and Leo´n, Castile-La Mancha, Catalonia, Extremadura,
Galicia, Community of Madrid, Murcia, Navarre, Valencian re-
gion, Sweden, Switzerland, the Netherlands, the UK, England/
Northern Ireland/Wales and UK, Scotland.
Countries or regions providing aggregated data are:
Albania, Belarus, Bulgaria, Croatia, Cyprus, Czech Republic,
Georgia, Israel, Italy, Latvia, Lithuania, Macedonia, Poland,
Portugal, Russia, Slovakia, Spain, Tunisia (Sfax region),
Turkey, Ukraine.
APPENDIX A2
Miscellaneous primary renal diseases: Nephropathy (intersti-
tial) due to analgesic drugs, nephropathy (interstitial) due to cis-
platinum, nephropathy (interstitial) due to cyclosporin A, lead-
induced nephropathy (interstitial), drug-induced nephropathy
(interstitial) not mentioned above, cystic kidney disease—
type unspecified, polycystic kidneys; infantile (recessive), med-
ullary cystic disease; including nephronophtisis, cystic
kidney disease—other specified type, hereditary/familial
nephropathy—type unspecified, hereditary nephritis with nerve
deafness (Alport’s Syndrome), cystinosis, primary oxalosis,
Fabry’s disease, hereditary nephropathy—other specified type,
renal hypoplasia (congenital)—type unspecified, oligomega-
nephronic hypoplasia, congenital renal dysplasia with or with-
out urinary tract malformation, syndrome of agenesis of
abdominal muscles (prune belly), renal vascular disease due to
polyarteritis, Wegener’s granulomatosis, ischaemic renal dis-
ease/cholesterol embolism, glomerulonephritis related to liver
cirrhosis, cryoglobulinemic glomerulonephritis, myelomatosis/
light-chain deposit disease, amyloid, lupus erythematosus,
Henoch–Schonlein purpura, Goodpasture’s Syndrome, systemic
sclerosis (scleroderma), haemolytic uraemic syndrome (includ-
ing Moschcowitz Syndrome), multi-system disease—other (not
mentioned above), tubular necrosis (irreversible) or cortical ne-
crosis (different from 88), tuberculosis, gout, nephrocalcinosis
and hypercalcaemic nephropathy, Balkan nephropathy, kidney
tumour, traumatic or surgical loss of kidney, other identified re-
nal disorders.
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